Other

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

This Notice is associated with the COVID-19 Supplemental funding through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” The National Cancer Institute (NCI) intends to publish a Funding Opportunity Announcement (FOA) as a Request for Applications (RFAs) to solicit applications to establish Serological Sciences Centers of Excellence of collaborating investigators and an RFA for research projects.

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Early Independence Award applications must be submitted in response to RFA-RM-20-014.

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in select scientific areas using the following funding mechanisms:

Supports individuals or teams proposing COVID-19-related projects that are inherently risky and untested but have the potential to create or overturn fundamental paradigms. An anonymized review process will be used.

The Substance Abuse and Mental Health Services Administration (SAMHSA) is accepting applications for fiscal year (FY) 2020 COVID-19 Emergency Response for Suicide Prevention (Short Title: COVID-19 ERSP) grants. SAMHSA recognizes there are currently 57.8 million Americans living with mental and/or substance use disorders (National Survey on Drug Use and Health, 2018). Currently, suicide is the tenth leading cause of death in our nation.

This notice announces the opportunity to apply for funding under the Rural Communities Opioid Response Program – Planning (RCORP-Planning). RCORP is a multi-year HRSA initiative with the goal of reducing morbidity and mortality resulting from substance use disorder (SUD), including opioid use disorder (OUD), in high risk rural communities. This funding opportunity, RCORP-Planning, will advance RCORP’s overall goal by strengthening and expanding the capacity of rural communities to provide SUD/OUD prevention, treatment, and recovery services.

The Rheumatology Research Foundation is issuing a notice of special interest (NOSI) to highlight the availability of funds for projects exploring the relationships between rheumatic and musculoskeletal diseases and SARS-CoV-2, the virus that causes COVID-19.

The Foundation accepts submissions within the following scientific categories:
•Basic Science
•Translational Science
•Clinical Science
•Health Services Research
•Patient- or Practice-Centered Research

Recent clinical experience has shown that people with diabetes are at higher risk of death from COVID19 and that COVID-19 drives an increased risk of hyperglycemia and other complications in those with and without diabetes. This is in addition to the risk due to advanced age and chronic disease. Both the biological mechanisms underlying this risk and how to minimize it remain poorly understood. There is an urgent need for research to understand the impact of diabetes on COVID-19 and vice versa. This is true at a basic and clinical level.